Perceptive Advisors LLC Buys 50,628 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Perceptive Advisors LLC grew its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 8.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 640,274 shares of the company’s stock after acquiring an additional 50,628 shares during the quarter. Perceptive Advisors LLC owned about 1.23% of EyePoint Pharmaceuticals worth $5,570,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in EYPT. Deerfield Management Company L.P. Series C raised its holdings in EyePoint Pharmaceuticals by 51.4% in the second quarter. Deerfield Management Company L.P. Series C now owns 877,790 shares of the company’s stock worth $7,637,000 after purchasing an additional 298,196 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in shares of EyePoint Pharmaceuticals by 842.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 476,250 shares of the company’s stock worth $4,143,000 after buying an additional 425,717 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of EyePoint Pharmaceuticals by 112.5% during the 2nd quarter. Renaissance Technologies LLC now owns 152,800 shares of the company’s stock worth $1,329,000 after acquiring an additional 80,900 shares in the last quarter. Greenwich Wealth Management LLC purchased a new stake in EyePoint Pharmaceuticals during the second quarter valued at approximately $94,000. Finally, Arizona State Retirement System lifted its position in EyePoint Pharmaceuticals by 9.7% during the second quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $115,000 after acquiring an additional 1,171 shares during the last quarter. 99.41% of the stock is owned by institutional investors.

EyePoint Pharmaceuticals Trading Down 1.1 %

NASDAQ EYPT opened at $7.98 on Monday. The stock has a market capitalization of $427.09 million, a price-to-earnings ratio of -4.38 and a beta of 1.59. The stock has a 50-day moving average of $8.70 and a 200 day moving average of $12.19. EyePoint Pharmaceuticals, Inc. has a twelve month low of $5.67 and a twelve month high of $30.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.03). The company had revenue of $9.48 million during the quarter, compared to analyst estimates of $11.61 million. EyePoint Pharmaceuticals had a negative net margin of 172.29% and a negative return on equity of 43.24%. Equities analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Insider Activity

In related news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $10.06, for a total value of $116,947.50. Following the sale, the director now directly owns 1,850 shares in the company, valued at approximately $18,611. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.74% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, June 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of EyePoint Pharmaceuticals in a report on Thursday, June 20th. Chardan Capital restated a “buy” rating and set a $28.00 price objective on shares of EyePoint Pharmaceuticals in a report on Friday, June 28th. Jefferies Financial Group began coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They issued a “buy” rating and a $15.00 target price for the company. Finally, StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a research report on Saturday, September 21st. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $30.57.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.